If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

A recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

HealthDay News — Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in the Journal of the American Medical Association.

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...

placebo. Perspective from Shannon C. Scott, DO, FACOFP Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

The sodium glucose co-transporter 2 (SGLT2) functions in the proximal tubule to reabsorb the bulk of filtered glucose. SGLT2 inhibitors have been developed to promote renal glucose excretion to ...

However, the new study offers an alternative by combining moderate calorie reduction with dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor. Dapagliflozin helps regulate blood ...

Share on Pinterest An SGLT-2 inhibitor drug plus a moderately calorie-restrictive diet may be the best approach for achieving diabetes remission. Image credit: Xvision/Getty Images. About 828 ...